Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma - Poll - MDSpire

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

  • By

  • Rajshekhar Chakraborty

  • Heloise Cheruvalath

  • Anannya Patwari

  • Aniko Szabo

  • Carolina Schinke

  • Binod Dhakal

  • Suzanne Lentzsch

  • Anita D’Souza

  • Ghulam Rehman Mohyuddin

  • Kelley Julian

  • Shonali Midha

  • Patrick Costello

  • Martin Kaiser

  • Melissa Ng Liet Hing

  • Simon J. Harrison

  • Edward R. Scheffer Cliff

  • Meera Mohan

  • August 12, 2024

  • 0 min

Share

Original Source(s)

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

  • by Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng Liet Hing, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan

  • August 12, 2024

Related Content

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

A propensity score matching study on clinical characteristics and risk factors of herpes zoster in malignant tumor